Cargando…

Botulinum toxin type A for neuropathic pain in patients with spinal cord injury

OBJECTIVE: To evaluate the analgesic effect of botulinum toxin type A (BTX‐A) on patients with spinal cord injury‐associated neuropathic pain. METHODS: The effect of BTX‐A on 40 patients with spinal cord injury‐associated neuropathic pain was investigated using a randomized, double‐blind, placebo‐co...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Zee‐A, Song, Dae Heon, Oh, Hyun‐Mi, Chung, Myung Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825405/
https://www.ncbi.nlm.nih.gov/pubmed/26814620
http://dx.doi.org/10.1002/ana.24605
_version_ 1782426214687834112
author Han, Zee‐A
Song, Dae Heon
Oh, Hyun‐Mi
Chung, Myung Eun
author_facet Han, Zee‐A
Song, Dae Heon
Oh, Hyun‐Mi
Chung, Myung Eun
author_sort Han, Zee‐A
collection PubMed
description OBJECTIVE: To evaluate the analgesic effect of botulinum toxin type A (BTX‐A) on patients with spinal cord injury‐associated neuropathic pain. METHODS: The effect of BTX‐A on 40 patients with spinal cord injury‐associated neuropathic pain was investigated using a randomized, double‐blind, placebo‐controlled design. A 1‐time subcutaneous BTX‐A (200U) injection was administered to the painful area. Visual analogue scale (VAS) scores (0–100mm), the Korean version of the short‐form McGill Pain Questionnaire, and the World Health Organization WHOQOL‐BREF quality of life assessment were evaluated prior to treatment and at 4 and 8 weeks after the injection. RESULTS: At 4 and 8 weeks after injection, the VAS score for pain was significantly reduced by 18.6 ± 16.8 and 21.3 ± 26.8, respectively, in the BTX‐A group, whereas it was reduced by 2.6 ± 14.6 and 0.3 ± 19.5, respectively, in the placebo group. The pain relief was associated with preservation of motor or sensory function below the neurological level of injury. Among the responders in the BTX‐A group, 55% and 45% reported pain relief of 20% or greater at 4 and 8 weeks, respectively, after the injection, whereas only 15% and 10% of the responders in the placebo group reported a similar level of pain relief. Improvements in the score for the physical health domain of the WHOQOL‐BREF in the BTX‐A group showed a marginal trend toward significance (p = 0.0521) at 4 weeks after the injection. INTERPRETATION: These results indicate that BTX‐A may reduce intractable chronic neuropathic pain in patients with spinal cord injury. Ann Neurol 2016;79:569–578
format Online
Article
Text
id pubmed-4825405
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48254052016-04-18 Botulinum toxin type A for neuropathic pain in patients with spinal cord injury Han, Zee‐A Song, Dae Heon Oh, Hyun‐Mi Chung, Myung Eun Ann Neurol Research Articles OBJECTIVE: To evaluate the analgesic effect of botulinum toxin type A (BTX‐A) on patients with spinal cord injury‐associated neuropathic pain. METHODS: The effect of BTX‐A on 40 patients with spinal cord injury‐associated neuropathic pain was investigated using a randomized, double‐blind, placebo‐controlled design. A 1‐time subcutaneous BTX‐A (200U) injection was administered to the painful area. Visual analogue scale (VAS) scores (0–100mm), the Korean version of the short‐form McGill Pain Questionnaire, and the World Health Organization WHOQOL‐BREF quality of life assessment were evaluated prior to treatment and at 4 and 8 weeks after the injection. RESULTS: At 4 and 8 weeks after injection, the VAS score for pain was significantly reduced by 18.6 ± 16.8 and 21.3 ± 26.8, respectively, in the BTX‐A group, whereas it was reduced by 2.6 ± 14.6 and 0.3 ± 19.5, respectively, in the placebo group. The pain relief was associated with preservation of motor or sensory function below the neurological level of injury. Among the responders in the BTX‐A group, 55% and 45% reported pain relief of 20% or greater at 4 and 8 weeks, respectively, after the injection, whereas only 15% and 10% of the responders in the placebo group reported a similar level of pain relief. Improvements in the score for the physical health domain of the WHOQOL‐BREF in the BTX‐A group showed a marginal trend toward significance (p = 0.0521) at 4 weeks after the injection. INTERPRETATION: These results indicate that BTX‐A may reduce intractable chronic neuropathic pain in patients with spinal cord injury. Ann Neurol 2016;79:569–578 John Wiley and Sons Inc. 2016-02-16 2016-04 /pmc/articles/PMC4825405/ /pubmed/26814620 http://dx.doi.org/10.1002/ana.24605 Text en © 2016 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Han, Zee‐A
Song, Dae Heon
Oh, Hyun‐Mi
Chung, Myung Eun
Botulinum toxin type A for neuropathic pain in patients with spinal cord injury
title Botulinum toxin type A for neuropathic pain in patients with spinal cord injury
title_full Botulinum toxin type A for neuropathic pain in patients with spinal cord injury
title_fullStr Botulinum toxin type A for neuropathic pain in patients with spinal cord injury
title_full_unstemmed Botulinum toxin type A for neuropathic pain in patients with spinal cord injury
title_short Botulinum toxin type A for neuropathic pain in patients with spinal cord injury
title_sort botulinum toxin type a for neuropathic pain in patients with spinal cord injury
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825405/
https://www.ncbi.nlm.nih.gov/pubmed/26814620
http://dx.doi.org/10.1002/ana.24605
work_keys_str_mv AT hanzeea botulinumtoxintypeaforneuropathicpaininpatientswithspinalcordinjury
AT songdaeheon botulinumtoxintypeaforneuropathicpaininpatientswithspinalcordinjury
AT ohhyunmi botulinumtoxintypeaforneuropathicpaininpatientswithspinalcordinjury
AT chungmyungeun botulinumtoxintypeaforneuropathicpaininpatientswithspinalcordinjury